Clinical Trial Update: Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating efficacy and safety of ofatumumab versus placebo in relapsing multiple sclerosis with open-label extension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Ofatumumab (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2022-02-18